Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools

J Hepatol. 2014 Jul;61(1):178-9. doi: 10.1016/j.jhep.2014.02.035. Epub 2014 Mar 21.

Authors

Lucio Boglione¹, Amedeo De Nicolò², Giovanni Di Perri², Antonio D'Avolio²

Affiliations

¹ Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy. Electronic address: lucio.boglione@unito.it.
² Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy.

PMID: 24662301
DOI: 10.1016/j.jhep.2014.02.035

No abstract available

Publication types

Letter
Comment

MeSH terms

Antiviral Agents / administration & dosage*
Female
Hepacivirus / classification*
Hepatitis C, Chronic / drug therapy*
Humans
Interferon-alpha / administration & dosage*
Male
Polyethylene Glycols / administration & dosage*
Ribavirin / administration & dosage*

Substances

Antiviral Agents
Interferon-alpha
Polyethylene Glycols
Ribavirin